New subcutaneous treatment reduces pain, increases the chances of survival of patients with breast cancer -
breast cancer treatments are usually painful, time and aggressive, which leads to prolonged a long hospitalization, medical personnel and the high economic costs.
to fight against this problem, it is a new subcutaneous treatment option for HER2 cancer, which are tumors that produce excess HER2 protein and represent 20 percent of cases.
This new line subcutaneous trastuzumab reduces pain and increases the chances of patient survival, even women who are metastatic phase, which means that the cancer has moved to other areas.
traditional use of trastuzumab treatment an intravenous line and requires the doctor to determine a dose based on the patient's weight, which sometimes causes the waste of medicines because the amount administered is less than that that exists in the bottles, producing an economic loss for both the healthcare facility and the patient.
further, the administration time is three to four hours, a situation that is solved with the subcutaneous treatment with fixed dose that requires only five minutes from placement.
This new method eliminates the pain and investment it requires less medical personnel for administration, reducing the economic costs.
Dr. Laura Torrecillas, medical oncologist assigned to oncology services Centro Médico Nacional 20 de noviembre de ISSSTE, said that "a patient being treated with therapy, the advantages of quality and expectancy add life to less time in administration and less aggression, is a patient who will focus more on treatment. "
Since April this year, trastuzumab subcutaneous is on the list of essential medicines and the health system catalog entries.
in Mexico, according to the Instituto Nacional de Estadística y Geografía (INEGI), during 2014, 29 new cases were diagnosed by all 100 thousand women over 20 with breast cancer, which is the leading cause of cancer death in women in our country.
has this, Dr. Juan Pablo Benítez, medical Director of oncology Roche said that for 15 years, trastuzumab had been the standard drug treatment for HER2 breast cancer because of its effectiveness, but this new option offers more benefits.
He explained that in 2012 the results of the HannaH clinical study were published in which it was demonstrated the efficacy and safety of trastuzumab subcutaneously in the treatment of cancer HER2-positive breast.
"based on the results of this study, the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) granted health registration trastuzumab subcutaneously in 2015".
EmoticonEmoticon